Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
jianpi yishen huazhuo granules
- Development stage
- Phase 2
- Lead developer
- Guizhou Bailing Group Pharmaceutical
- Administration
- Oral
01
Overview
Jianpi Yishen Huazhuo granules is a Traditional Chinese Medicine (TCM) formulation developed by Xiyuan Hospital of the China Academy of Traditional Chinese Medicine for the treatment of vascular dementia. The formulation is designed to address the TCM syndromes of spleen–kidney deficiency and phlegm–blood stasis, which are hypothesized to contribute to the pathogenesis of cognitive impairment following cerebrovascular events. By tonifying the spleen and kidney and promoting the resolution of phlegm and blood stasis, the granules aim to improve cognitive performance and daily functioning. It is currently undergoing Phase 2 clinical evaluation in China to establish its safety and therapeutic efficacy.
- Other names
- Jianpi Yishen Huazhuo granules
Beyond the preview
Go deeper on jianpi yishen huazhuo granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on jianpi yishen huazhuo granules.